Acetylspiramycin (25-200 mg/kg/day; Oral gavage (p.o.); 7 days) can significantly enhance the lymphocyte proliferation response of CBA/H mice to PHA, and reduce the activity of lymphokine in a dose-dependent manner[3].
Acetylspiramycin (50-200 mg/kg/day; Oral gavage (p.o.); 14 days) in CBA/H mouse models can increase the efficiency of phagocytosis in mice[4].
| Animal Model: | CBA/H mice |
| Dosage: | 25-200 mg/kg/day |
| Administration: | Oral gavage (p.o.), 7 days |
| Result: | Decreased lymphokine activity in a dose-dependent manner |
| Animal Model: | CBA/H mice[4] |
| Dosage: | 50-200 mg/kg/day |
| Administration: | Oral gavage (p.o.), 14 days |
| Result: | Increased the efficiency of phagocytosis in mice. |
